

Hiroto Inaba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7470889/publications.pdf>

Version: 2024-02-01

172
papers

8,039
citations

61984

43
h-index

54911

84
g-index

173
all docs

173
docs citations

173
times ranked

10337
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2013, 381, 1943-1955.	13.7	879
2	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 955-959.	1.6	563
3	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. <i>Lancet Oncology, The</i> , 2010, 11, 543-552.	10.7	514
4	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. <i>Nature Genetics</i> , 2016, 48, 367-373.	21.4	389
5	Pediatric acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, 2524-2539.	3.5	313
6	Glucocorticoid use in acute lymphoblastic leukaemia. <i>Lancet Oncology, The</i> , 2010, 11, 1096-1106.	10.7	282
7	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	27.8	236
8	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3625-3632.	1.6	188
9	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. <i>Lancet Oncology, The</i> , 2015, 16, 465-474.	10.7	177
10	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. <i>Blood</i> , 2012, 120, 468-472.	1.4	176
11	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019, 37, 3377-3391.	1.6	169
12	Crenolanib is active against models of drug-resistant FLT3-ITD ⁺ positive acute myeloid leukemia. <i>Blood</i> , 2013, 122, 3607-3615.	1.4	159
13	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 3293-3300.	1.6	142
14	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. <i>PLoS Genetics</i> , 2015, 11, e1005262.	3.5	128
15	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 386-391.	1.6	122
16	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 81-112.	4.9	102
17	Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD ⁺ Positive Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 5758-5768.	7.0	87
18	Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. <i>Lancet Oncology, The</i> , 2017, 18, 1238-1248.	10.7	87

#	ARTICLE	IF	CITATIONS
19	Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 1926.	2.4	86
20	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. <i>Cancer</i> , 2008, 113, 522-529.	4.1	83
21	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. <i>Haematologica</i> , 2014, 99, 865-872.	3.5	77
22	Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2019, 5, 1456.	7.1	77
23	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. <i>Blood</i> , 2015, 126, 2896-2899.	1.4	76
24	Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51. <i>PLoS ONE</i> , 2013, 8, e79106.	2.5	76
25	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. , 2019, 7, 81.		74
26	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€Directed Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 326-337.	5.0	71
27	Skeletal, neuromuscular and fitness impairments among children with newly diagnosed acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1004-1011.	1.3	70
28	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. <i>Blood</i> , 2018, 132, 264-276.	1.4	70
29	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021, 2, 284-299.	13.2	70
30	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015, 126, 1575-1584.	1.4	69
31	Childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 259-276.	2.5	68
32	Immunotherapy in pediatric acute lymphoblastic leukemia. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 595-610.	5.9	65
33	The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 236-239.	1.5	63
34	Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia. <i>Clinical Infectious Diseases</i> , 2017, 65, 1790-1798.	5.8	62
35	Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Childrenâ€™s Research Hospital Approach. <i>Frontiers in Pediatrics</i> , 2017, 5, 258.	1.9	62
36	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. <i>Journal of Clinical Oncology</i> , 2019, 37, 2051-2061.	1.6	61

#	ARTICLE	IF	CITATIONS
37	Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2014, 120, 1514-1519.	4.1	58
38	Effect of body mass index on the outcome of children with acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 5989-5996.	4.1	56
39	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. <i>Journal of Clinical Oncology</i> , 2015, 33, 610-615.	1.6	56
40	Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. <i>Cancer</i> , 2010, 116, 2020-2030.	4.1	53
41	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 1985-1992.	4.1	53
42	Longitudinal Changes in Body Mass and Composition in Survivors of Childhood Hematologic Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3991-3997.	1.6	52
43	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. <i>Journal of the National Cancer Institute</i> , 2011, 103, 893-905.	6.3	50
44	Intracellular cytokine profile of T cells from children with acute lymphoblastic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 165-172.	4.2	48
45	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 329-344.	13.2	44
46	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1110-1120.	4.1	43
47	Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 4248-4259.	4.1	43
48	Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 4036-4043.	4.1	41
49	Peripheral neuropathy in children and adolescents treated for cancer. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 744-754.	5.6	41
50	Ontogeny and Sorafenib Metabolism. <i>Clinical Cancer Research</i> , 2012, 18, 5788-5795.	7.0	40
51	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. <i>Leukemia</i> , 2021, 35, 3272-3277.	7.2	40
52	Natural killer cell therapy in children with relapsed leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1468-1472.	1.5	39
53	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2017, 128, 369-380.	8.2	39
54	Parainfluenza Virus Infections in Children With Hematologic Malignancies. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 855-859.	2.0	38

#	ARTICLE	IF	CITATIONS
55	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28040.	1.5	38
56	Integrated Genomic Analysis Identifies <i>UBTF</i> Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 194-207.	5.0	38
57	Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2012, 156, 109-117.	2.5	37
58	The role of ^{18}F -FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 845-853.	2.5	37
59	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. <i>Cancer Research</i> , 2016, 76, 117-126.	0.9	36
60	Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. <i>Cancer</i> , 2017, 123, 3791-3798.	4.1	34
61	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2072-2081.	1.6	34
62	Treatment outcome in older patients with childhood acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 6253-6259.	4.1	32
63	Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020, 126, 593-601.	4.1	32
64	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. <i>British Journal of Haematology</i> , 2015, 168, 94-101.	2.5	31
65	Down-regulation of Fas-Associated Phosphatase-1 (FAP-1) in Interleukin-2-Activated T Cells. <i>Cellular Immunology</i> , 1998, 186, 103-110.	3.0	29
66	Pulmonary function after whole lung irradiation in pediatric patients with solid malignancies. <i>Cancer</i> , 2012, 118, 1450-1456.	4.1	29
67	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1546-1551.	1.5	29
68	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2013, 119, 2061-2066.	4.1	27
69	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. <i>Nature Communications</i> , 2019, 10, 2189.	12.8	26
70	mRNA expression of Fas receptor (CD95)-associated proteins (Fas-associated phosphatase-1/FAP-1,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 leukaemia/lymphoma cell lines. <i>British Journal of Haematology</i> , 1997, 99, 325-330.	2.5	25
71	Interferon- γ sensitizes osteosarcoma cells to fas-induced apoptosis by up-regulating fas receptors and caspase-8. <i>Pediatric Blood and Cancer</i> , 2004, 43, 729-736.	1.5	24
72	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. <i>Cancer</i> , 2010, 116, 98-105.	4.1	24

#	ARTICLE	IF	CITATIONS
73	Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1331-1339.	2.5	24
74	Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1161-1164.	1.5	22
75	Bone mineral density in children with acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 1025-1035.	4.1	21
76	Association of Bacteremic Sepsis With Long-term Neurocognitive Dysfunction in Pediatric Patients With Acute Lymphoblastic Leukemia. <i>JAMA Pediatrics</i> , 2018, 172, 1092.	6.2	21
77	Allogeneic graft-versus-hepatoblastoma effect. <i>Pediatric Blood and Cancer</i> , 2006, 46, 501-505.	1.5	20
78	Defective cell cycle induction by IL-2 in naive T-cells antigen stimulated in the presence of refractory T-lymphocytes. <i>International Immunology</i> , 2006, 18, 1043-1054.	4.0	20
79	Predicting success of desensitization after pegaspargase allergy. <i>Blood</i> , 2020, 135, 71-75.	1.4	20
80	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 73.e1-73.e9.	1.2	20
81	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	5.2	20
82	BK Virus-Induced Tubulointerstitial Nephritis in a Child with Acute Lymphoblastic Leukemia. <i>Journal of Pediatrics</i> , 2007, 151, 215-217.	1.8	18
83	Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management. <i>Cancer</i> , 2021, 127, 3067-3081.	4.1	18
84	mRNA expression of variant fas molecules in acute leukemia cells. , 1999, 62, 150-158.		17
85	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 294-302.	1.5	17
86	Pulmonary alveolar proteinosis in pediatric leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 51, 66-70.	1.5	16
87	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. <i>British Journal of Haematology</i> , 2012, 156, 275-279.	2.5	16
88	Acute Megakaryoblastic Leukemia Without <i>GATA1</i> Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e230-e233.	1.6	15
89	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 7320-7330.	7.0	14
90	Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib. <i>Haematologica</i> , 2019, 104, e218-e221.	3.5	14

#	ARTICLE	IF	CITATIONS
91	A case of hemoglobin SC disease with cold agglutinin-induced hemolysis. <i>American Journal of Hematology</i> , 2005, 78, 37-40.	4.1	13
92	Randomized trial of 2 dosages of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 1313-1320.	4.1	13
93	Definition of cure in childhood acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 2490-2496.	4.1	12
94	Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 983-986.	1.4	12
95	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. <i>Clinical and Translational Science</i> , 2019, 12, 641-647.	3.1	12
96	Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor. <i>Oncoimmunology</i> , 2019, 8, 1599637.	4.6	12
97	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	4.1	12
98	Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27669.	1.5	11
99	Epitopes and Functional Responses Defined by a Panel of Anti-Fas (CD95) Monoclonal Antibodies. <i>Hybridoma</i> , 1999, 18, 391-398.	0.6	10
100	Spinal epidural lipomatosis in children with hematologic malignancies. <i>Annals of Hematology</i> , 2011, 90, 1067-1074.	1.8	10
101	Longitudinal Trajectories of Neurocognitive Functioning in Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Psychology</i> , 2021, 46, 168-178.	2.1	10
102	Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study. <i>Leukemia</i> , 2021, 35, 2258-2273.	7.2	10
103	Alternative formulations of sorafenib for use in children. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1642-1646.	1.5	9
104	Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e177-e181.	2.5	9
105	Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, E38-41.	1.5	8
106	Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 3386-3397.	5.2	8
107	Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent. <i>Cancer Genetics</i> , 2018, 224-225, 12-20.	0.4	7
108	Ultrasound has limited diagnostic utility in children with acute lymphoblastic leukemia developing pancreatitis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28730.	1.5	7

#	ARTICLE	IF	CITATIONS
109	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 794-802.	4.7	7
110	Whole-body joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28336.	1.5	6
111	Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group. <i>Blood</i> , 2019, 134, 652-652.	1.4	6
112	Translocation t(6;9)(p22;q34)/DEK-NUP214 rearranged Pediatric AML: A Retrospective International Study. <i>Blood</i> , 2012, 120, 538-538.	1.4	6
113	Functional Significance of Adhesion Molecules in Fas-Dependent Apoptotic Cell Death Induced by Interleukin-2-Activated T Cells. <i>Immunological Investigations</i> , 1998, 27, 309-322.	2.0	5
114	Diagnostic Challenge in Recurrent Skin Rash After Autologous Bone Marrow Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 525-528.	0.6	5
115	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , 2017, 58, 247-250.	1.3	5
116	Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	5
117	Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28244.	1.5	5
118	Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia. <i>Modern Pathology</i> , 2021, 34, 2050-2054.	5.5	5
119	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 655-664.	2.3	5
120	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. <i>Haematologica</i> , 2022, 107, 371-380.	3.5	5
121	Herpes Simplex Virus Pneumonia in a Patient with Ependymoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 108-111.	0.6	4
122	Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy. <i>Cancer</i> , 2021, 127, 3202-3213.	4.1	4
123	Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients. <i>Blood</i> , 2015, 126, 252-252.	1.4	4
124	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. <i>Blood</i> , 2016, 128, 454-454.	1.4	4
125	Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1. <i>International Journal of Oncology</i> , 2005, 27, 573.	3.3	3
126	In Vivo Suppression of Naive CD4 T Cell Responses by IL-2- and Antigen-Stimulated T Lymphocytes in the Absence of APC Competition. <i>Journal of Immunology</i> , 2008, 181, 3323-3335.	0.8	3

#	ARTICLE	IF	CITATIONS
127	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. <i>Blood</i> , 2020, 136, 39-40.	1.4	3
128	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1073-1073.	1.4	3
129	Acute Appendicitis in Children with Leukemia: Unique Diagnostic Process, Management, and Outcome. <i>Blood</i> , 2015, 126, 4872-4872.	1.4	3
130	Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. <i>Blood</i> , 2016, 128, 3937-3937.	1.4	3
131	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. <i>Blood Advances</i> , 2022, 6, 2824-2834.	5.2	3
132	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and <i>FLT3</i> -Internal Tandem Duplication. <i>Clinical Cancer Research</i> , 2022, 28, 2536-2546.	7.0	3
133	Obesity and height in children and adolescents with acute lymphoblastic leukemia and its future management. <i>Oncotarget</i> , 2019, 10, 1233-1234.	1.8	2
134	Integrative genomic analysis of B-lymphoblastic lymphoma with intrachromosomal amplification of chromosome 21. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28357.	1.5	2
135	Metabolic Acidosis in a Pediatric Patient with Leukemia and Fungal Infection. <i>Clinical Chemistry</i> , 2020, 66, 518-522.	3.2	2
136	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. <i>Blood</i> , 2018, 132, 2697-2697.	1.4	2
137	Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies. <i>Blood</i> , 2016, 128, 584-584.	1.4	2
138	High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1421-1421.	1.4	2
139	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2017, 130, 883-883.	1.4	2
140	Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care. <i>Children</i> , 2021, 8, 1200.	1.5	2
141	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia. <i>Science Advances</i> , 2022, 8, eabj1360.	10.3	2
142	Acute myeloid leukemia. , 0, , 395-420.		1
143	Evaluation of Chest Radiographs of Children with Newly Diagnosed Acute Lymphoblastic Leukemia. <i>Journal of Pediatrics</i> , 2020, 223, 120-127.e3.	1.8	1
144	mRNA expression of variant fas molecules in acute leukemia cells. <i>American Journal of Hematology</i> , 1999, 62, 150-158.	4.1	1

#	ARTICLE	IF	CITATIONS
145	Abstract 2033: Germline mutations in ETV6 confer risk of thrombocytopenia and acute lymphocytic leukemia. , 2015, , .		1
146	Pulmonary Function in Pediatric survivors of non-Malignant Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2008, 112, 2136-2136.	1.4	1
147	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. Blood, 2010, 116, 495-495.	1.4	1
148	Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome. Blood, 2016, 128, 585-585.	1.4	1
149	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3406-3406.	1.4	1
150	Clinical manifestations of sepsis during nonfatal bacteremia in pediatric patients undergoing therapy for acute lymphoblastic leukemia. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
151	Intensive but tender care for infant ALL. Blood, 2020, 136, 1797-1798.	1.4	0
152	Preventing weight gain in children with acute lymphoblastic leukemia by early nutritional intervention. Pediatric Blood and Cancer, 2021, 68, e28965.	1.5	0
153	Reduced intensity chemotherapy with tyrosine kinase inhibitor and blinatumomab in a pediatric patient with Philadelphia chromosome-positive ALL and mechanical heart valves. Pediatric Blood and Cancer, 2021, 68, e28924.	1.5	0
154	Inhibition of Class I PI3K Isoforms Restores the Sensitivity of Acute Myelogenous Leukemia Cells to Multi-Tyrosine Kinase Inhibitors in the Bone Marrow Microenvironment.. Blood, 2009, 114, 1734-1734.	1.4	0
155	Longitudinal Analysis of Antibody Response to Immunization in Pediatric Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 795-795.	1.4	0
156	Minimal Residual Disease-directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.. Blood, 2009, 114, 16-16.	1.4	0
157	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. Blood, 2010, 116, 498-498.	1.4	0
158	Parainfluenza Virus Infections In Children with Cancer. Blood, 2010, 116, 3909-3909.	1.4	0
159	Longitudinal Analysis of Body Mass and Composition in Survivors of Pediatric Hematological Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1991-1991.	1.4	0
160	Abstract 2739: Panobinostat potentiates the cytotoxic effects of ara-C and daunorubicin on acute myeloid leukemia cells through suppressing the DNA damage response. , 2012, , .		0
161	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. Blood, 2013, 122, 490-490.	1.4	0
162	Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3620-3620.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG). <i>Blood</i> , 2014, 124, 3670-3670.	1.4	0
164	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1299-1299.	1.4	0
165	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. <i>Blood</i> , 2016, 128, 2838-2838.	1.4	0
166	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
167	Traumatic and Bloody Lumbar Puncture at Diagnosis in Children with Acute Lymphoblastic Leukemia: A St. Jude Total XV and Total XVI Cohort Study. <i>Blood</i> , 2018, 132, 1380-1380.	1.4	0
168	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2665-2665.	1.4	0
169	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. <i>Blood</i> , 2021, 138, 2295-2295.	1.4	0
170	Amino Acid Stress Response Genes Promote L-Asparaginase Resistance in Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3304-3304.	1.4	0
171	Integrated Genomic Analysis Identifies LIBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, LBA-4-LBA-4.	1.4	0
172	Bone mineral density (BMD) deficits in adult survivors of childhood cancer: Attributable risks and long-term consequences.. <i>Journal of Clinical Oncology</i> , 2022, 40, e22021-e22021.	1.6	0